BB Biotech: NAV outperformance not reflected in share price - SEB
29 juli, 11:29
BB Biotech delivered a strong Q2 performance, with NAV outperforming the Nasdaq Biotech Index (NBI) by 3.5 percentage points in CHF. Yet the share price discount to NAV widened from 6.9% to 12.9% despite robust underlying execution. The discount has since tightened to ~10% by late July, which is in line with the average 12-month discount to the NBI.
SEB Research
This research has been commissioned by the company. Only for professional investors resident in EEA member states. Reports may not be distributed to the US or other jurisdictions where to do so would be unlawful. Please see the disclaimer tab for any details of investment banking services recently provided by SEB that could be considered relevant to the subject matter of this research.
Ämnen i artikeln
BB Biotech: NAV outperformance not reflected in share price - SEB
29 juli, 11:29
BB Biotech delivered a strong Q2 performance, with NAV outperforming the Nasdaq Biotech Index (NBI) by 3.5 percentage points in CHF. Yet the share price discount to NAV widened from 6.9% to 12.9% despite robust underlying execution. The discount has since tightened to ~10% by late July, which is in line with the average 12-month discount to the NBI.
SEB Research
This research has been commissioned by the company. Only for professional investors resident in EEA member states. Reports may not be distributed to the US or other jurisdictions where to do so would be unlawful. Please see the disclaimer tab for any details of investment banking services recently provided by SEB that could be considered relevant to the subject matter of this research.
Ämnen i artikeln
Aktieanalys
Aktieanalys
Marknadsöversikt
1 DAG %
Senast
1 mån
